- | Abpro Corp
Biotechs Developing Innovative Ways to Activate the Immune System Against COVID-19
Abpro Corp., a biotechnology company developing next generation antibody therapies for severe disease, is targeting a more robust antibody response with its therapeutic, ABP 300, which is based on neutralizing monoclonal antibodies.
- | Rocket Pharmaceuticals
Latest data give Rocket clear path forward in rare CV disease Danon
While an adverse event in the high-dose cohort continues to outline the limits oh high volume AAV dosing…
- | Fountain Therapeutics
View From The Inside: What’s Shaping Biopharma In 2021 And Beyond?
About a year ago, Life Science Leader Chief Editor Rob Wright posed questions to several biopharma leaders for a column in the 2019 iteration of this annual Outlook issue. At least two of those questions, had they been asked just a month or so later, would have surely yielded very different responses than they did in December 2019: What impact would a U.S. economic slowdown have on biopharma manufacturing, and what should biopharma do in the next three to five years to reduce risk to global supply chains posed by natural disasters?
- | GigaGen
2020 Top 10 Innovations
Enter GigaGen’s Surge platform, which uses single-cell sequencing to “capture and recreate” libraries of antibodies from blood donors.
- | Cerevance
Trial Drug Shows Promise in Treating Cognitive Impairment Associated with Schizophrenia
Last week, privately-owned Cerevance released data from a Phase Ib biomarker study of its oral compound, CVN058, evaluating the potential of the medication as a treatment for cognitive impairment associated with schizophrenia (CIAS).
- | Arrowhead Pharmaceuticals
Genetic medicines find a heartbeat
“RNA interference is often better than antibodies because of the catalytic process that you can generally use,” said Chris Anzalone, CEO of Arrowhead Pharmaceuticals. A drug like inclisiran can cut LDL cholesterol in half with only two injections per year, whereas Praluent and Repatha injections are given every 2 to 4 weeks.
- | Scynexis
Emerging fungal resistance: A hidden epidemic
Invasive fungal infections are becoming increasingly common and often pose a serious public health threat, claiming the lives of more than 1.5 million people worldwide each year.
